Abstract
Abstract Introduction Keratinocyte growth factor (palifermin) is used for the prevention of mucositis in adults following autologous and allogeneic hematopoietic stem cell transplantation (HSCT). It is known that palifermin decreases length of initial hospital stay, mean number of days of total parenteral nutrition and the use of opioids for pain control in oral mucositis in adults. There are limited data evaluating palifermin use in children following autologous HSCT. Aim The aim of this study was to analyze the efficacy and safety of palifermin in children and adolescents following autologous HSCT. Material and methods The study included 81 consecutive patients. Results of efficacy and safety of palifermin in 18 patients were compared to data of 63 patients not treated with palifermin. Results and discussion Palifermin decreased the incidence of severe oral mucositis (grade 3–4 WHO) by 19% (44% vs. 63%), however it did not contribute to the duration of oral mucositis and total parenteral nutrition use. There were no differences in opioid use, incidence of fever of unknown origin, severe infection, engraftment and gastrointestinal hemorrhage between groups. Five-year overall survival was better in patients treated with palifermin. Only in one patient generalized, itching rash was observed after palifermin administration. Conclusions Palifermin decreases incidence of severe oral mucositis and improves overall survival in children undergoing autologous HSCT.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.